{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Redwood+City&page=11&state=California", "query": { "state": "California", "city": "Redwood City", "page": 11 }, "page_size": 10 }, "pagination": { "page": 11, "page_size": 10, "total_count": 289, "total_pages": 29, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Redwood+City&page=12&state=California&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Redwood+City&page=10&state=California&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-07T16:11:21.168Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03907046", "title": "Anticoagulation in ICH Survivors for Stroke Prevention and Recovery", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Intracerebral Hemorrhage", "Atrial Fibrillation" ], "interventions": [ { "name": "Apixaban", "type": "DRUG" }, { "name": "Aspirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 700, "start_date": "2020-01-28", "completion_date": "2027-04", "has_results": false, "last_update_posted_date": "2026-05-08", "last_synced_at": "2026-11-07T16:11:21.168Z", "location_count": 186, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 141 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03907046" }, { "nct_id": "NCT00785291", "title": "Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Estrogen Receptor Negative", "Estrogen Receptor Positive", "HER2/Neu Negative", "HER2/Neu Positive", "Progesterone Receptor Negative", "Progesterone Receptor Positive", "Recurrent Breast Carcinoma", "Stage IIIC Breast Cancer AJCC v6", "Stage IV Breast Cancer AJCC v6 and v7" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Ixabepilone", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 799, "start_date": "2008-10-13", "completion_date": "2017-06-15", "has_results": true, "last_update_posted_date": "2026-06-23", "last_synced_at": "2026-11-07T16:11:21.168Z", "location_count": 703, "location_summary": "Scottsdale, Arizona • Fort Smith, Arkansas • Jonesboro, Arkansas + 472 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00785291" }, { "nct_id": "NCT00822120", "title": "S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma", "Nonneoplastic Condition" ], "interventions": [ { "name": "bleomycin sulfate", "type": "BIOLOGICAL" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "ABVD regimen", "type": "DRUG" }, { "name": "BEACOPP regimen", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "dacarbazine", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "procarbazine hydrochloride", "type": "DRUG" }, { "name": "vinblastine sulfate", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 371, "start_date": "2009-07", "completion_date": "2022-06-30", "has_results": true, "last_update_posted_date": "2022-08-18", "last_synced_at": "2026-11-07T16:11:21.168Z", "location_count": 423, "location_summary": "Tucson, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 290 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00822120" }, { "nct_id": "NCT00915018", "title": "Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Neratinib", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Puma Biotechnology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 479, "start_date": "2009-08-21", "completion_date": "2018-06-28", "has_results": true, "last_update_posted_date": "2018-08-22", "last_synced_at": "2026-11-07T16:11:21.168Z", "location_count": 36, "location_summary": "Oxnard, California • Santa Rosa, California • Plainville, Connecticut + 32 more", "locations": [ { "city": "Oxnard", "state": "California" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Plainville", "state": "Connecticut" }, { "city": "Boynton Beach", "state": "Florida" }, { "city": "Deerfield Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00915018" }, { "nct_id": "NCT00003389", "title": "Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Bleomycin", "type": "DRUG" }, { "name": "Vinblastine", "type": "DRUG" }, { "name": "Dacarbazine", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Mechlorethamine", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Radiotherapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Eastern Cooperative Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 854, "start_date": "1999-06-17", "completion_date": "2016-05", "has_results": true, "last_update_posted_date": "2023-06-29", "last_synced_at": "2026-11-07T16:11:21.168Z", "location_count": 517, "location_summary": "Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 329 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Berkeley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003389" }, { "nct_id": "NCT01275677", "title": "Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HER2/Neu Positive", "Progesterone Receptor Positive", "Recurrent Breast Carcinoma", "Stage IA Breast Cancer AJCC v7", "Stage IB Breast Cancer AJCC v7", "Stage IIA Breast Cancer AJCC v6 and v7", "Stage IIB Breast Cancer AJCC v6 and v7", "Stage IIIA Breast Cancer AJCC v7", "Stage IIIC Breast Cancer AJCC v7" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Trastuzumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 3270, "start_date": "2011-02-08", "completion_date": "2025-06-02", "has_results": true, "last_update_posted_date": "2025-07-14", "last_synced_at": "2026-11-07T16:11:21.168Z", "location_count": 1259, "location_summary": "Anniston, Alabama • Mobile, Alabama • Anchorage, Alaska + 797 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT01275677" }, { "nct_id": "NCT01535066", "title": "S1200: Acupuncture, Sham Acupuncture, or Wait List for Joint Symptoms Related to Aromatase Inhibitors in Pts W/Early-Stage Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Breast Cancer", "Pain" ], "interventions": [ { "name": "acupuncture therapy", "type": "PROCEDURE" }, { "name": "sham acupuncture", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 226, "start_date": "2012-05-16", "completion_date": "2018-07-01", "has_results": false, "last_update_posted_date": "2022-12-07", "last_synced_at": "2026-11-07T16:11:21.168Z", "location_count": 47, "location_summary": "Antioch, California • Fremont, California • Los Angeles, California + 36 more", "locations": [ { "city": "Antioch", "state": "California" }, { "city": "Fremont", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "Redwood City", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01535066" }, { "nct_id": "NCT02506153", "title": "Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Metastatic Cutaneous Melanoma", "Metastatic Mucosal Melanoma", "Metastatic Non-Cutaneous Melanoma", "Non-Cutaneous Melanoma", "Recurrent Cutaneous Melanoma", "Recurrent Mucosal Melanoma", "Recurrent Non-Cutaneous Melanoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Recombinant Interferon Alfa-2b", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1301, "start_date": "2015-11-10", "completion_date": "2027-01-23", "has_results": true, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-11-07T16:11:21.168Z", "location_count": 552, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 379 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02506153" }, { "nct_id": "NCT00053898", "title": "Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "anastrozole", "type": "DRUG" }, { "name": "tamoxifen citrate", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "NSABP Foundation Inc", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "FEMALE", "summary": "Female only" }, "enrollment_count": 3104, "start_date": "2003-01", "completion_date": "2016-05", "has_results": true, "last_update_posted_date": "2018-09-20", "last_synced_at": "2026-11-07T16:11:21.168Z", "location_count": 724, "location_summary": "Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 499 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Opelika", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT00053898" }, { "nct_id": "NCT04251052", "title": "A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Ovarian Carcinoma" ], "interventions": [ { "name": "Bilateral Salpingectomy", "type": "PROCEDURE" }, { "name": "Bilateral Salpingectomy with Oophorectomy", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Transvaginal Ultrasound", "type": "PROCEDURE" }, { "name": "Ultrasound Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "OTHER" ], "sponsor": "NRG Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "35 Years", "maximum_age": "50 Years", "sex": "FEMALE", "summary": "35 Years to 50 Years · Female only" }, "enrollment_count": 1956, "start_date": "2020-09-01", "completion_date": "2047-06-30", "has_results": false, "last_update_posted_date": "2026-11-06", "last_synced_at": "2026-11-07T16:11:21.168Z", "location_count": 620, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Goodyear, Arizona + 406 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT04251052" } ] }